LG

Lawrence Gozlan

Alterity Therapeutics Limited | Non-Executive Director
Mr Gozlan, a biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level expertise and to manage investments for high-net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (the Queensland Investment Corporation), an investment fund with over A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd and gained senior corporate finance experience advising life sciences companies at Deloitte.

Companies and Roles

Company
Title
Tenure
Since
ATH
Alterity Therapeutics Limited
  • Non-Executive Director
12yrs, 11mthAug 2011
OPT
Opthea Limited
  • Non-Executive Director
3yrs, 11mthJul 2020
ENL
Enlitic Inc
  • Non-Executive Chairman
  • Non-Executive Director
4yrs, 9mthSep 2019

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
ENL
Enlitic Inc
28/03/24N/AN/A2,855,988N/A
OPT
Opthea Limited
21/12/23N/A1,877,3575,000,000N/A
ATH
Alterity Therapeutics Limited
31/08/23N/AN/A7,000,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
OPT
Opthea Limited
21/12/23
Issued
500,000$0.470$235,000Issue of options
ATH
Alterity Therapeutics Limited
14/12/22
Expiry
1,250,000$0.010$12,500Options expired
OPT
Opthea Limited
01/03/21
Issued
2,000,000$1.580$3,160,000Issue of options
ATH
Alterity Therapeutics Limited
18/09/20
Issued
7,000,000$0.054$378,000Issue of options
ATH
Alterity Therapeutics Limited
19/12/17
Buy
250,000$0.076$19,000Exercise of options. As per announcement on 22/12/2017